查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1980184

生物標記市場規模、佔有率、成長及全球產業分析：按類型和應用的洞察，2026-2034年預測

Biomarkers Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 110 Pages | 商品交期: 請詢問到貨日

價格

生物標記市場成長要素

全球生物標記市場在2025年達到869.5億美元，2026年成長至975億美元，預計在2034年達到2,175.8億美元，預測期內年複合成長率（CAGR）高達12.2%。北美將在2025年引領市場，佔36.93%的市場佔有率。這主要得益於個人化醫療的積極應用、主要企業的巨額投資以及先進的醫療基礎設施。

生物標記是能夠反映器官、組織或細胞生物學狀態的可測量指標。它們在疾病診斷、藥物研發、安全性評估和生物醫學研究中非常重要。生物標記可根據其功能（例如診斷、預後、預測或其他生物標記功能）及其生物學特徵（例如基因組學、蛋白質組學和代謝體學）進行廣泛分類。

市場促進因素

全球生物標記市場的主要驅動力是生物標記診斷應用的不斷擴展。生物標記在個人化醫療中發揮著非常重要的作用，有助於根據患者的臨床和基因特徵最佳化治療方案。這在腫瘤學領域尤其重要，因為基於生物標記的治療方法能夠提高治療效果。癌症、心血管疾病和神經退化性疾病的日益普遍也進一步推動了市場需求。

疾病診斷技術的進步、對基於生物標記的藥物研發投入的增加以及伴隨診斷的普及是推動市場成長的關鍵因素。例如，Pfizer公司的Selgently（Maraviloc）利用一種名為Trofile的生物標記檢測來評估HIV患者對治療的反應。同樣，DiamiR公司在2019年因其對腦源性微型RNA作為神經退化外周生物標記的研究而獲得了阿茲海默症基金會的獎項。

市場限制因素

挑戰包括研發成本高、監管障礙以及生物標記檢測需要專用設備。一些新興市場認知度較低，以及將生物標記資料整合到臨床決策中的複雜性，也可能是阻礙成長的因素。

細分分析

依適應症：

  • 預計到2025年，腫瘤學將成為市場的主要驅動力，並在2026年保持其最大市場佔有率 49.44%的地位，這主要得益於癌症患病率的上升以及基於生物標記的診斷方法在標靶治療中的日益普及。
  • 由於肌鈣蛋白等生物標記在心血管疾病診斷的應用日益廣泛，循環系統領域蓬勃發展。
  • 神經病學和其他適應症是新興領域，其發展動力來自神經退化性疾病疾病和罕見疾病的生物標記研究。

依最終用戶分類：

  • 診斷和研究實驗室是最大的終端用戶群體，並得到了生物標記開發的大量津貼和投資的支持，預計到2026年將佔市場佔有率的52.89%。
  • 製藥和生物技術公司、醫院和專科診所也是推動其應用的其他終端用戶。

區域趨勢

北美：

  • 市場規模：預計到2025年將達到 321.2億美元，到2026年將達到 358.7億美元。
  • 推動該成長的主要因素包括個人化醫療的廣泛應用、研發領域的大規模投資以及有利的監管核准。預計到2026年，光是美國市場規模就將達到311.7億美元。

歐洲：

  • 歐盟體外診斷醫療設備法規結構（IVDR）、完善的臨床研究基礎設施以及生物技術公司與醫療機構之間的合作，為該市場提供了支持。預計2026年，英國市場規模將達46.2億美元，德國市場規模將達80.2億美元。

亞太地區：

  • 由於癌症和心血管疾病的日益普遍，預計市場將顯著成長。到2026年，日本市場預計將達到73.4億美元，中國66.6億美元，印度26.5億美元。對基於生物標記的藥物研發投入的增加推動該技術的應用。

中東、非洲和拉丁美洲：

  • 由於全球公司的進入、醫療基礎設施的改善以及對基於生物標記的診斷的日益重視，新興地區有望實現成長。

主要市場參與者

生物標記市場高度分散，由Roche、Abbott和Thermo Fisher Scientific等公司主導，並受益於強大的研發實力和診斷檢測領域的創新。其他主要企業包括Bio-Rad Laboratories、CENTOGENE NV、Axon Medchem、Sino Biological、R&D Systems、BioVision和Myriad RBM。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機會

第4章 主要考察

  • 主要市場參與者推出新產品
  • 依疾病分類的主要國家/地區，2025年患病率
  • 2025年主要國家及地區癌症發生率
  • 產業重大發展動態 - 併購與合作
  • 個人化醫療中的生物標記概述

第5章 2021-2034年全球生物標記市場分析、洞察與預測

  • 主要發現與總結
  • 市場分析、洞察與預測：依適應症
    • 腫瘤學
    • 循環系統
    • 神經病學
    • 其他
  • 市場分析、洞察與預測：依最終用戶分類
    • 製藥和生物技術公司
    • 診斷與研究實驗室
    • 醫院和專科診所
    • 其他
  • 市場分析、洞察與預測：依地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美生物標記市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章 歐洲生物標記市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章 亞太生物標記市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章 拉丁美洲生物標記市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章 中東和非洲生物標記市場分析、洞察與預測（2021-2034年）

  • 國家
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 主要行業趨勢
  • 全球市場佔有率分析（2025年）
  • 公司簡介
    • F. Hoffmann-La Roche Ltd.
    • Abbott
    • Thermo Fisher Scientific
    • Bio-Rad Laboratories, Inc
    • CENTOGENE NV
    • Axon Medchem
    • Sino Biological Inc.
    • R&D System
    • BioVision Inc.
    • Myriad RBM
    • Other Prominent Players

第12章 戰略建議

Product Code: FBI102173

Growth Factors of biomarkers Market

The global biomarkers market was valued at USD 86.95 billion in 2025 and is projected to grow to USD 97.5 billion in 2026, reaching USD 217.58 billion by 2034, reflecting a robust CAGR of 12.2% during the forecast period. North America dominated the market in 2025, accounting for a 36.93% share, driven by strong adoption in personalized medicine, significant investments by key players, and advanced healthcare infrastructure.

Biomarkers, or biological markers, are measurable indicators of the biological state of an organ, tissue, or cell. They are critical in disease diagnosis, drug discovery, safety assessment, and biomedical research. Biomarkers are broadly classified based on function, including diagnostic, prognostic, predictive, and other biomarkers, and on biological properties such as genomics, proteomics, and metabolomics.

Market Drivers

The global biomarkers market is primarily driven by the growing diagnostic applications of biomarkers. Biomarkers play an essential role in personalized medicine, helping tailor treatment plans based on a patient's clinical and genetic profile. This is particularly valuable in oncology, where biomarker-guided therapies enhance treatment efficacy. The increasing prevalence of cancer, cardiovascular, and neurodegenerative diseases further fuels demand.

Technological advancements in disease diagnosis, rising investment in biomarker-based drug discovery, and adoption of companion diagnostics are key factors accelerating market growth. For example, Pfizer's Selzentry (Maraviroc) utilizes the Trofile assay biomarker to determine patient response to HIV treatment. Similarly, DiamiR received an award from the Alzheimer's Drug Discovery Foundation in 2019 for research on circulating brain-enriched microRNAs as peripheral biomarkers of neurodegeneration.

Market Restraints

Challenges include high research and development costs, regulatory hurdles, and the need for specialized equipment for biomarker detection. Limited awareness in some emerging markets and the complexity of integrating biomarker data into clinical decision-making may also restrain growth.

Segmentation Analysis

By Indication:

  • Oncology dominated the market in 2025 and is expected to hold the largest share in 2026 with 49.44%, driven by rising cancer prevalence and increased use of biomarker-based diagnostics for targeted therapies.
  • Cardiology is growing due to the increasing use of biomarkers like troponin for diagnosing cardiovascular diseases.
  • Neurology and other indications are emerging segments, fueled by biomarker research in neurodegenerative and rare diseases.

By End User:

  • Diagnostics and research laboratories are the largest end-user segment, expected to hold 52.89% of the market in 2026, supported by extensive grants and investment in biomarker development.
  • Pharmaceutical & biotechnology companies, hospitals, and specialty clinics represent other end-users driving adoption.

Regional Insights

North America:

  • Market size: USD 32.12 billion in 2025, projected USD 35.87 billion in 2026.
  • Growth is fueled by strong adoption in personalized medicine, extensive R&D investment, and favorable regulatory approvals. The U.S. market alone is projected to reach USD 31.17 billion in 2026.

Europe:

  • Supported by the EU's regulatory framework for in-vitro diagnostics (IVDR), robust clinical research infrastructure, and collaborations between biotech companies and healthcare institutions. The UK market is projected at USD 4.62 billion and Germany at USD 8.02 billion by 2026.

Asia Pacific:

  • Market growth is expected to be significant due to the increasing prevalence of cancer and cardiovascular diseases. The Japan market is projected at USD 7.34 billion, China at USD 6.66 billion, and India at USD 2.65 billion by 2026. Rising investments in biomarker-based drug discovery are boosting adoption.

Middle East, Africa, and Latin America:

  • Emerging regions are witnessing growth due to the entry of global players, improved healthcare infrastructure, and increased focus on biomarker-based diagnostics.

Key Market Players

The biomarkers market is highly fragmented, led by F. Hoffmann-La Roche Ltd., Abbott, and Thermo Fisher Scientific, Inc., supported by strong R&D and innovation in diagnostic assays. Other notable players include Bio-Rad Laboratories, CENTOGENE N.V., Axon Medchem, Sino Biological Inc., R&D Systems, BioVision Inc., and Myriad RBM.

Recent Developments:

  • January 2025: Launch of AI-engineered designer proteins for regenerative medicine.
  • February 2025: Expansion of RNAscope(TM) probe portfolio for biomarker validation.
  • November 2024: Achieved IVDR certification for R&D Systems hematology controls.
  • May 2023: FDA clearance for B*R*A*H*M*S PlGF plus KRYPTOR immunoassays.

Conclusion

The biomarkers market is set for significant growth, from USD 86.95 billion in 2025 to USD 217.58 billion by 2034, fueled by the increasing adoption of personalized medicine, advancements in diagnostics, and the rising prevalence of chronic diseases. Strong investments in R&D, the introduction of novel biomarkers, and collaborations between biotech companies are expected to further drive market expansion across regions, particularly in North America and Asia Pacific.

Segmentation By Indication

  • Oncology
  • Cardiology
  • Neurology
  • Others

By End User

  • Pharmaceutical & Biotechnology Companies
  • Diagnostics & Research Laboratories
  • Hospitals & Specialty Clinics
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. New Product Launches, by Key Market Players
  • 4.2. Prevalence by Disease Indication, By Key Countries/ Region, 2025
  • 4.3. Incidence of Cancer, By Key Countries/ Key Region,2025
  • 4.4. Key industry Developments - Mergers, Acquisitions and Partnerships
  • 4.5. Overview of Biomarkers In Personalized Medicine

5. Global Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. Oncology
    • 5.2.2. Cardiology
    • 5.2.3. Neurology
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Pharmaceutical & Biotechnology Companies
    • 5.3.2. Diagnostics & Research Laboratories
    • 5.3.3. Hospitals & Specialty Clinics
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. Oncology
    • 6.2.2. Cardiology
    • 6.2.3. Neurology
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Pharmaceutical & Biotechnology Companies
    • 6.3.2. Diagnostics & Research Laboratories
    • 6.3.3. Hospitals & Specialty Clinics
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. Oncology
    • 7.2.2. Cardiology
    • 7.2.3. Neurology
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Pharmaceutical & Biotechnology Companies
    • 7.3.2. Diagnostics & Research Laboratories
    • 7.3.3. Hospitals & Specialty Clinics
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. Oncology
    • 8.2.2. Cardiology
    • 8.2.3. Neurology
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Pharmaceutical & Biotechnology Companies
    • 8.3.2. Diagnostics & Research Laboratories
    • 8.3.3. Hospitals & Specialty Clinics
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. Oncology
    • 9.2.2. Cardiology
    • 9.2.3. Neurology
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Pharmaceutical & Biotechnology Companies
    • 9.3.2. Diagnostics & Research Laboratories
    • 9.3.3. Hospitals & Specialty Clinics
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis, Insights and Forecast - By Indication
    • 10.2.1. Oncology
    • 10.2.2. Cardiology
    • 10.2.3. Neurology
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Pharmaceutical & Biotechnology Companies
    • 10.3.2. Diagnostics & Research Laboratories
    • 10.3.3. Hospitals and Specialty Clinics
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.4.1. GCC Countries
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.3.1. F. Hoffmann-La Roche Ltd.
      • 11.3.1.1. Overview,
      • 11.3.1.2. Products & services,
      • 11.3.1.3. SWOT analysis,
      • 11.3.1.4. Recent developments,
      • 11.3.1.5. strategies,
      • 11.3.1.6. financials (based on availability)
    • 11.3.2. Abbott
      • 11.3.2.1. Overview,
      • 11.3.2.2. Products & services,
      • 11.3.2.3. SWOT analysis,
      • 11.3.2.4. Recent developments,
      • 11.3.2.5. strategies,
      • 11.3.2.6. financials (based on availability)
    • 11.3.3. Thermo Fisher Scientific
      • 11.3.3.1. Overview,
      • 11.3.3.2. Products & services,
      • 11.3.3.3. SWOT analysis,
      • 11.3.3.4. Recent developments,
      • 11.3.3.5. strategies,
      • 11.3.3.6. financials (based on availability)
    • 11.3.4. Bio-Rad Laboratories, Inc
      • 11.3.4.1. Overview,
      • 11.3.4.2. Products & services,
      • 11.3.4.3. SWOT analysis,
      • 11.3.4.4. Recent developments,
      • 11.3.4.5. strategies,
      • 11.3.4.6. financials (based on availability)
    • 11.3.5. CENTOGENE N.V.
      • 11.3.5.1. Overview,
      • 11.3.5.2. Products & services,
      • 11.3.5.3. SWOT analysis,
      • 11.3.5.4. Recent developments,
      • 11.3.5.5. strategies,
      • 11.3.5.6. financials (based on availability)
    • 11.3.6. Axon Medchem
      • 11.3.6.1. Overview,
      • 11.3.6.2. Products & services,
      • 11.3.6.3. SWOT analysis,
      • 11.3.6.4. Recent developments,
      • 11.3.6.5. strategies,
      • 11.3.6.6. financials (based on availability)
    • 11.3.7. Sino Biological Inc.
      • 11.3.7.1. Overview,
      • 11.3.7.2. Products & services,
      • 11.3.7.3. SWOT analysis,
      • 11.3.7.4. Recent developments,
      • 11.3.7.5. strategies,
      • 11.3.7.6. financials (based on availability)
    • 11.3.8. R&D System
      • 11.3.8.1. Overview,
      • 11.3.8.2. Products & services,
      • 11.3.8.3. SWOT analysis,
      • 11.3.8.4. Recent developments,
      • 11.3.8.5. strategies,
      • 11.3.8.6. financials (based on availability)
    • 11.3.9. BioVision Inc.
      • 11.3.9.1. Overview,
      • 11.3.9.2. Products & services,
      • 11.3.9.3. SWOT analysis,
      • 11.3.9.4. Recent developments,
      • 11.3.9.5. strategies,
      • 11.3.9.6. financials (based on availability)
    • 11.3.10. Myriad RBM
      • 11.3.10.1. Overview,
      • 11.3.10.2. Products & services,
      • 11.3.10.3. SWOT analysis,
      • 11.3.10.4. Recent developments,
      • 11.3.10.5. strategies,
      • 11.3.10.6. financials (based on availability)
    • 11.3.11. Other Prominent Players
      • 11.3.11.1. Overview,
      • 11.3.11.2. Products & services,
      • 11.3.11.3. SWOT analysis,
      • 11.3.11.4. Recent developments,
      • 11.3.11.5. strategies,
      • 11.3.11.6. financials (based on availability)

12. Strategic Recommendation

List of Tables

  • Table 1: Global Biomarkers Market Revenue (US$ Mn) Forecast, by Indication, 2021-2034
  • Table 2: Global Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 3: Global Biomarkers Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 4: North America Biomarkers Market Revenue (US$ Mn) Forecast, by Indication, 2021-2034
  • Table 5: North America Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 6: North America Biomarkers Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 7: Europe Biomarkers Market Revenue (US$ Mn) Forecast, by Indication, 2021-2034
  • Table 8: Europe Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 9: Europe Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 10: Asia Pacific Biomarkers Market Revenue (US$ Mn) Forecast, by Indication, 2021-2034
  • Table 11: Asia Pacific Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 12: Asia Pacific Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Latin America Biomarkers Market Revenue (US$ Mn) Forecast, by Indication, 2021-2034
  • Table 14: Latin America Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 15: Latin America Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Middle East & Africa Biomarkers Market Revenue (US$ Mn) Forecast, by Indication, 2021-2034
  • Table 17: Middle East & Africa Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 18: Middle East & Africa Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Biomarkers Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
  • Figure 2: Global Biomarkers Market Value Share (%), by Indication 2025 & 2034
  • Figure 3: Global Biomarkers Market Forecast (US$ Mn), by Oncology, 2021-2034
  • Figure 4: Global Biomarkers Market Forecast (US$ Mn), by Cardiology, 2021-2034
  • Figure 5: Global Biomarkers Market Forecast (US$ Mn), by Neurology, 2021-2034
  • Figure 6: Global Biomarkers Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 7: Global Biomarkers Market Value Share (%), by End User, 2025 & 2034
  • Figure 8: Global Biomarkers Market Forecast (US$ Mn), by Pharmaceutical and Biotechnology Companies, 2021-2034
  • Figure 9: Global Biomarkers Market Forecast (US$ Mn), by Diagnostics and Research Laboratories, 2021-2034
  • Figure 10: Global Biomarkers Market Forecast (US$ Mn), by Hospitals and Specialty Clinics, 2021-2034
  • Figure 11: Global Biomarkers Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 12: Global Biomarkers Market Value (US$ Mn), by Region, 2025 & 2034
  • Figure 13: North America Biomarkers Market Value (US$ Mn), by Indication, 2025 & 2034
  • Figure 14: North America Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 15: North America Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 16: North America Biomarkers Market Value Share (%), by End User, 2025
  • Figure 17: North America Biomarkers Market Value (US$ Mn), By Country, 2025 & 2034
  • Figure 18: North America Biomarkers Market Value Share (%), By Country, 2025
  • Figure 19: Europe Biomarkers Market Value (US$ Mn), by Indication, 2025 & 2034
  • Figure 20: Europe Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 21: Europe Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 22: Europe Biomarkers Market Value Share (%), by End User, 2025
  • Figure 23: Europe Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 24: Europe Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 25: Asia Pacific Biomarkers Market Value (US$ Mn), by Indication, 2025 & 2034
  • Figure 26: Asia Pacific Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 27: Asia Pacific Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 28: Asia Pacific Biomarkers Market Value Share (%), by End User, 2025
  • Figure 29: Asia Pacific Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 30: Asia Pacific Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 31: Latin America Biomarkers Market Value (US$ Mn), by Indication, 2025 & 2034
  • Figure 32: Latin America Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 33: Latin America Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 34: Latin America Biomarkers Market Value Share (%), by End User, 2025
  • Figure 35: Latin America Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Latin America Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Middle East & Africa Biomarkers Market Value (US$ Mn), by Indication, 2025 & 2034
  • Figure 38: Middle East & Africa Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 39: Middle East & Africa Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 40: Middle East & Africa Biomarkers Market Value Share (%), by End User, 2025
  • Figure 41: Middle East & Africa Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 42: Middle East & Africa Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 43: Global Biomarkers Market Share (%), By Company, 2025